Clinical Trials Directory

Trials / Unknown

UnknownNCT02319876

Expression of TIM-3 on Lymphocytes in Sepsis

Expression and the Clinical Significance of TIM-3 on Lymphocytes During Sepsis

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Changhai Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The current project was designed to examine the express TIM-3 on lymphocytes and monocytes and its role in immunosuppression during sepsis.

Detailed description

Immunosuppression is the leading cause of death in septic patients.Lymphocyte apoptosis has been recognized as an important step in the pathogenesis of sepsis. Previous studies indicated that T cell immunoglobulin and mucin protein 3 (TIM-3) is a type I cell surface protein and was identified as a marker of lymphocyte dysfunction. The current project was designed to examine the express TIM-3 on lymphocytes and monocytes and its further role in immunosuppression during sepsis.

Conditions

Timeline

Start date
2014-02-01
Primary completion
2015-12-01
Completion
2015-12-01
First posted
2014-12-18
Last updated
2015-07-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02319876. Inclusion in this directory is not an endorsement.